MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

fibromyalgia

  • Home
  • fibromyalgia
Optimizing Value in Fibromyalgia Care: High-Dose Duloxetine and Pregabalin Outperform Amitriptyline in Lifetime Cost-Effectiveness Models
Posted innews Psychiatry Rheumatology

Optimizing Value in Fibromyalgia Care: High-Dose Duloxetine and Pregabalin Outperform Amitriptyline in Lifetime Cost-Effectiveness Models

Posted by By MedXY 02/06/2026
A recent decision analytical model identifies duloxetine 120 mg as the most cost-effective treatment for moderate-to-severe fibromyalgia, providing superior clinical outcomes at a marginal cost increase compared to amitriptyline, particularly when societal impacts are considered.
Read More
FDA Approves Tonmya: First Nonopioid Sublingual Treatment Targeting Sleep in Fibromyalgia
Posted inNeurology news Specialties

FDA Approves Tonmya: First Nonopioid Sublingual Treatment Targeting Sleep in Fibromyalgia

Posted by By MedXY 08/19/2025
The FDA has approved Tonmya (sublingual cyclobenzaprine) as the first new fibromyalgia therapy in 15 years, targeting nonrestorative sleep to alleviate pain, fatigue, and cognitive symptoms in adults.
Read More
  • GLP1R R131Q Variant: A Genetic Key to Preserving β-Cell Function and Enhancing GLP-1RA Efficacy in Type 2 Diabetes
  • Evaluating the Specificity of Capillary Leak Indices in Heart Failure: Implications for Clinical Practice
  • Unveiling Non-Genetic Influences on Hereditary Ataxia: Insights from SCA6 and SCA27B Cohorts
  • Enhancing Parathyroid Gland Preservation in Total Thyroidectomy: Efficacy of Near-Infrared Autofluorescence Probe (PTeye) Versus Visual Identification
  • Long-Term Survival Benefit of Daratumumab with Lenalidomide and Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Insights from the MAIA Final Analysis
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis prostate cancer public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top